Article

Clinical Impact of Interruption in Adjuvant Trastuzumab Therapy in Patients with Operable HER-2 Positive Breast Cancer

2020-10-23

Abstract excerpt

<h4>Background: </h4> Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) experiencing treatment interruption or discontinuation. <h4>Methods:</h4> The primary objective of the study was to evaluate disease...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fb92911a-e1dd-5ac1-a122-873390b0f9bd
DOI: 10.21203/rs.3.rs-60091/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical Impact of Interruption in Adjuvant Trastuzumab Therapy in Patients with Operable HER-2 Positive Breast CancerDOI 10.21203/rs.3.rs-60091/v2Read

Adjuvant Weekly Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer without Risk Factors of Cardiotoxicity. Possibility of Omitting Cardiac Monitoring during Treatment.Semantic proximity Read

Prevalence and Effects of Late Cardiotoxicity induced by Anthracyclines and/or Anti- HER2 Antibodies in Patients with Breast Cancer: a real world studySemantic proximity Read

The Value of Oral Selective Estrogen Receptor Degraders in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer after Progression on ≥ 1 Line of Endocrine Therapy: Systematic Review and Meta-analysisSemantic proximity Read

The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.Semantic proximity Read

Risk of heart disease following breast cancer: results from a population-based cohort studySemantic proximity Read

De-escalating Treatment Strategies for Patients with Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Early-Stage Breast CancerSemantic proximity Read

Preventing metastatic recurrence in low-risk ER/PR+ breast cancer patients – a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapySemantic proximity Read

Left Atrial Volume Index, Other Systolic and Diastolic Transthoracic Echocardiographic Parameters as Early Predictors for Asymptomatic Trastuzumab Target Cancer Therapy-Related Cardiac Dysfunction among HER2-Positive Breast Cancer Patients at a Tertiary Medical Center in Metro Manila – a Single-Center Prospective Cohort StudySemantic proximity Read

Facts and controversies in the use of trastuzumab in the adjuvant setting.Semantic proximity Read

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.Semantic proximity Read

Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer.Semantic proximity Read

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.Semantic proximity Read